172 related articles for article (PubMed ID: 21398295)
41. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
Winters MA; Chary A; Eison R; Asmuth D; Holodniy M
J Med Virol; 2010 May; 82(5):791-8. PubMed ID: 20336744
[TBL] [Abstract][Full Text] [Related]
42. Low incidence of renal impairment observed in tenofovir-treated patients.
O'Donnell EP; Scarsi KK; Darin KM; Gerzenshtein L; Postelnick MJ; Palella FJ
J Antimicrob Chemother; 2011 May; 66(5):1120-6. PubMed ID: 21393145
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
[TBL] [Abstract][Full Text] [Related]
44. HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia.
Diong C; Raboud J; Li M; Cooper C;
HIV Med; 2011 Aug; 12(7):403-11. PubMed ID: 21244600
[TBL] [Abstract][Full Text] [Related]
45. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Nicola G; Pogliaghi M; Cossarini F; Salpietro S; Galli A; Della Torre L; Tambussi G; Lazzarin A; Castagna A
J Acquir Immune Defic Syndr; 2011 Apr; 56(4):e113-5. PubMed ID: 21350358
[No Abstract] [Full Text] [Related]
46. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.
Cattaneo D; Gervasoni C; Meraviglia P; Landonio S; Fucile S; Cozzi V; Baldelli S; Pellegrini M; Galli M; Clementi E
J Antimicrob Chemother; 2012 Feb; 67(2):460-4. PubMed ID: 22127581
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
[TBL] [Abstract][Full Text] [Related]
48. Resolution of autoimmune thrombocytopenia associated with raltegravir use in an HIV-positive patient.
Gentile I; Bonadies G; Buonomo AR; Minei G; Borrelli F; Foggia M; Chiurazzi F; Borgia G
Platelets; 2013; 24(7):574-7. PubMed ID: 23130846
[TBL] [Abstract][Full Text] [Related]
49. Antiretroviral therapy-associated diseases are common in the long-term.
Lanzafame M; Lattuada E; Zoppini G; Vento S
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):931-2. PubMed ID: 21182461
[No Abstract] [Full Text] [Related]
50. Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier García-Samaniego.
Puoti M; Bruno R; Castelli F; Filice G; Carosi G
HIV Clin Trials; 2002; 3(5):419-20. PubMed ID: 12407492
[No Abstract] [Full Text] [Related]
51. Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A; Nozza S; Bonora S; Castagna A; Gonzalez de Requena D; D'Avolio A; Lazzarin A; Di Perri G
J Antimicrob Chemother; 2011 Aug; 66(8):1932-4. PubMed ID: 21642649
[No Abstract] [Full Text] [Related]
52. A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.
Turkova A; Ball C; Gilmour-White S; Rela M; Mieli-Vergani G
J Antimicrob Chemother; 2009 Mar; 63(3):623-5. PubMed ID: 19164417
[No Abstract] [Full Text] [Related]
53. Raltegravir-induced DRESS syndrome.
Loulergue P; Mir O
Scand J Infect Dis; 2012 Oct; 44(10):802-3. PubMed ID: 22803794
[TBL] [Abstract][Full Text] [Related]
54. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Núñez M; González-Requena D; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
[TBL] [Abstract][Full Text] [Related]
55. Chronic liver disease in the human immunodeficiency virus patient.
Acharya C; Dharel N; Sterling RK
Clin Liver Dis; 2015 Feb; 19(1):1-22. PubMed ID: 25454294
[TBL] [Abstract][Full Text] [Related]
56. [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
Warpakowski A
MMW Fortschr Med; 2011 May; 153(18):50-1. PubMed ID: 21604599
[No Abstract] [Full Text] [Related]
57. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature.
Ripamonti D; Benatti SV; Di Filippo E; Ravasio V; Rizzi M
AIDS; 2014 Apr; 28(7):1077-9. PubMed ID: 24685746
[No Abstract] [Full Text] [Related]
58. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.
Madeddu G; Menzaghi B; Ricci E; Carenzi L; Martinelli C; di Biagio A; Parruti G; Orofino G; Mura MS; Bonfanti P;
AIDS; 2012 Nov; 26(18):2412-5. PubMed ID: 23032413
[TBL] [Abstract][Full Text] [Related]
59. [The pillars of modern HIV therapy: effectiveness, tolerance, compatibility].
MMW Fortschr Med; 2012 May; 154 Suppl 1():40-1. PubMed ID: 22916599
[No Abstract] [Full Text] [Related]
60. Noncirrhotic portal hypertension in HIV infection.
Vispo E; Morello J; Rodriguez-Novoa S; Soriano V
Curr Opin Infect Dis; 2011 Feb; 24(1):12-8. PubMed ID: 21157331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
